EUVIMEDEUVIMED entdecken
Crossref

Efficacy of [ 177 Lu]Lu-PSMA-617 With and Without Androgen Receptor Pathway Inhibitors for mAPM-R Prostate Cancer: Secondary Analysis of VISION

Omid Yazdanpanah, Jeremie Calais, Kim N Chi, Johann de Bono, Ghassan El-Haddad, Ken Herrmann, Karim Fizazi, Ayse Tuba Kendi, Bernd Krause, Michael J Morris, James Nagarajah, Luke Nordquist und 8 weitere

Journal of Nuclear Medicine · 19.11.2026 · jnumed.126.272954

DOI: 10.2967/jnumed.126.272954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 19.11.2026. Verfasst von Omid Yazdanpanah und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, California; oyazdanp@hs.uci.edu. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

VISION trial[177Lu]Lu-PSMA-617androgen receptor pathway inhibitorprostate cancersecondary clinical analysis

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, California; oyazdanp@hs.uci.edu.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Division of Medical Oncology, Department of Medicine, University of British Columbia, BC Cancer-Vancouver Center, Vancouver, British Columbia, Canada.
  • Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.
  • Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida.
  • Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Zitieren

APA

Yazdanpanah, O., Calais, J., Chi, K. N., de Bono, J., El-Haddad, G., Herrmann, K., Fizazi, K., Kendi, A. T., Krause, B., Morris, M. J., Nagarajah, J., Nordquist, L., Sartor, O., Rahbar, K., Tagawa, S. T., Vaishampayan, N., Ospina Gonzalez, D., Yue, Y., Carnahan, N., & Rezazadeh Kalebasty, A. (2026). Efficacy of [ 177 Lu]Lu-PSMA-617 With and Without Androgen Receptor Pathway Inhibitors for mAPM-R Prostate Cancer: Secondary Analysis of VISION. Journal of Nuclear Medicine, jnumed.126.272954. https://doi.org/10.2967/jnumed.126.272954

Vancouver

Yazdanpanah O, Calais J, Chi KN, de Bono J, El-Haddad G, Herrmann K, et al. Efficacy of [ 177 Lu]Lu-PSMA-617 With and Without Androgen Receptor Pathway Inhibitors for mAPM-R Prostate Cancer: Secondary Analysis of VISION. Journal of Nuclear Medicine. 2026:jnumed.126.272954. doi:10.2967/jnumed.126.272954

BibTeX
@article{Yazdanpanah2026,
  author = {Yazdanpanah, Omid and Calais, Jeremie and Chi, Kim N and de Bono, Johann and El-Haddad, Ghassan and Herrmann, Ken and Fizazi, Karim and Kendi, Ayse Tuba and Krause, Bernd and Morris, Michael J and Nagarajah, James and Nordquist, Luke and Sartor, Oliver and Rahbar, Kambiz and Tagawa, Scott T and Vaishampayan, Nitin and Ospina Gonzalez, Diego and Yue, Ye and Carnahan, Natalie and Rezazadeh Kalebasty, Arash},
  title = {Efficacy of [ 177 Lu]Lu-PSMA-617 With and Without Androgen Receptor Pathway Inhibitors for mAPM-R Prostate Cancer: Secondary Analysis of VISION},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.272954},
  doi = {10.2967/jnumed.126.272954}
}
Kostenlos starten →